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Objective: Cocaine Use Disorder (CUD) has been associated with multiple complications
and premature death. The purpose of the present study was to analyze the relationship
between baseline medical comorbidity and long-term medical outcomes
(i.e., hospitalization, death) in a cohort of patients primarily admitted for detoxification.
In addition, we aimed to analyze cause-specific mortality.
Methods: longitudinal study in CUD patients admitted for detoxification between 2001
and 2018. Substance use characteristics, laboratory parameters and medical comorbidity
by VACS Index were assessed at admission. Follow-up and health-related outcomes were
ascertained through visits and e-health records. Kaplan-Meier and Cox regression models
were used to analyze survival and predictors of hospitalization and death.
Results: 175 patients (77.7% men) were included. Age at admission was 35 years [IQR:
30–41 years], 59.4% of the patients being intranasal users, 33.5% injectors, and 7.1%
smokers. Almost 23% of patients had concomitant alcohol use disorder, 39% were
cannabis users and 9% opiate users. The median VACS Index score on admission was 10
points [IQR: 0–22]. After 12 years [IQR: 8.6–15 years] of follow-up there were 1,292
(80.7%) ED admissions and 308 (19.3%) hospitalizations. The incidence rate of ED
admission and hospitalization was 18.6 × 100 p-y (95% CI: 15.8–21.8 × 100 p-y).
Mortality rate was 1.4 × 100 p-y (95% CI: 0.9–2.0 × 100 p-y) and, baseline
comorbidity predicted hospitalization and mortality: those with VACS Index >40 were
3.5 times (HR:3.52, 95% CI: 1.19–10.4) more likely to dye with respect to patients with
VACS < 20.
Conclusion: addiction care warrants optimal stratification of medical comorbidity to
improve health outcomes and survival of CUD patients seeking treatment of the disorder.
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INTRODUCTION
Cocaine is the second most widely used illegal drug in Western
Europe after cannabis. According to the European Monitoring
Center for Drugs and Drug Addiction (EMCDDA), about four
million people aged 15–64 have used cocaine in the last year, and
the number of users has increased in recent years (European
Monitoring Center for Drugs and Drug Addiction (EMCDDA),
2019).
According to the EDADES population survey on alcohol and
drugs, 2% of the general population aged 15–64 in Spain uses cocaine
(Observatorio Español de las Drogas y las Adicciones, 2019).
Moreover, 54% of people who have used cocaine in the last year
have used it in the last month (Observatorio Español de las Drogas y
las Adicciones, 2019). In Catalonia (Spain), 24% of people who seek
treatment for substance use disorder (SUD) have a cocaine use
disorder (CUD), and this percentage has increased in recent years
(Subdirecció General de Drogodependències, 2018).
CUD has been associated with serious systemic complications,
frequent use of healthcare resources (i.e., emergency department
(ED) admissions, hospitalization), and premature death
(Degenhardt et al., 2011; Butler et al., 2017). In fact, cocaine use
can aggravate inflammatory diseases and alter immune functions
that favor the progression of cardiovascular, respiratory, or
infectious diseases (Taylor et al., 2016; Bachi et al., 2017). In
addition, it has been communicated that cocaine intoxication
can cause acute kidney injury, hepatotoxicity, and disseminated
intravascular coagulation (Vitcheva, 2012; Filho et al., 2019). On the
other hand, cocaine use has been associatedwith an increased risk of
HIV infection and hepatitis C virus (HCV) infection even in the
absence of injecting drug use (Macías et al., 2008; Deiss et al., 2012).
In addition, patients with CUD show a high prevalence of
psychiatric comorbidities, such as mood disorders (12–62%),
anxiety disorders (21–45%) and suicidal tendencies, among
others (Vergara-Moragues et al., 2012; Warden et al., 2016).
Cocaine use has also been associated with traffic accidents and
violence (Giovanardi et al., 2005; Pavarin et al., 2011).
Polysubstance use is common among cocaine users, especially
alcohol consumption, but the concurrent use of marijuana and
opiates is also prevalent, and has been associated with poor health
outcomes (Stinson et al., 2005; Timko et al., 2018). In the US, the
second wave of the National Epidemiologic Survey on Alcohol
and Related Conditions (NESARC) estimated that 79% of people
with CUD have a concomitant alcohol use disorder (AUD)
(Stinson et al., 2005).
A recent systematic review and meta-analysis on healthcare
utilization demonstrated that in SUD patients, hospitalization
and ED admissions are 5 and 7 times more frequent, respectively,
compared to the general population (Lewer et al., 2020). In
addition, the death rate of patients with CUD ranges from 0.5
to 6.2 × 100 person-years (p-y) and is considered to be 4 to
8 times higher than the death rate of the general population
(Arendt et al., 2011; Degenhardt et al., 2011).
Our hypothesis is that the chronicity of CUD is suggestive of
the presence of multiple medical complications, which leads to
the excessive use of healthcare resources (i.e., ED visits and
hospitalization). We aimed to analyze the relationship between
baseline medical comorbidity, use of health resources, and long-
term health outcomes among those seeking treatment for CUD.
MATERIALS AND METHODS
This was a longitudinal study of patients admitted to the
addiction treatment unit of a tertiary hospital (Germans Trias
i Pujol University Hospital) between January 2001 andMay 2018.
The unit admits patients diagnosed with SUD in an area in the
north of Barcelona (Spain) with 400,000 inhabitants. There were
837 admissions for addiction treatment between January 2001
and May 2018, of which 195 (23.3%) were due to CUD in 175
patients. In those who were admitted more than once, only the
first admission was analyzed.
The patients came from local primary care centers and from two
municipal outpatient addiction clinics, one in Badalona (250,000
inhabitants) and the other in Santa Coloma de Gramenet (150,000
inhabitants), both located in the metropolitan area of Barcelona
(Spain). The main admission criteria for CUD treatment were as
follows: failure in outpatient treatment, concurrent dependency on
other addictive drugs or alcohol, serious concurrent medical
problems, severe impairment of psychosocial functioning, lack of
family and social support, and use of crack or freebase cocaine or
intravenous cocaine abuse, among others.
All patients received a diagnosis of CUD according to the
Diagnostic and Statistical Manual of Mental Disorders, fourth Ed
(DSM-IV) and fifth Ed (DSM-5). Due to the transition from
DSM-IV to DSM-5, not all participants were evaluated under the
same DSM.
On admission, data on the use of cocaine and other substances
(i.e., alcohol, cannabis, opiates) were collected, including age of onset,
route of administration, and duration. DSM criteria were used to
diagnose AUD. Cannabis and opiates use was ascertained through
urinalysis at admission. For the purposes of this study, patients were
classified according to the route of cocaine administration as either
intranasal or non-intranasal users (i.e., injectors, smokers).
In all patients, blood samples were drawn for biochemical and
hematological parameters, and for serologic testing for human
immunodeficiency virus (HIV) infection and hepatitis C virus
(HCV) infection. Anthropometric data (i.e., height and weight)
were obtained as well.
Medical comorbidity on admission was analyzed using the VACS
Index (Veterans Aging Cohorts Study Index). VACS Index assigns a
score based on age and on blood parameters, such as hemoglobin,
platelets, aspartate and alanine aminotransferase levels, creatinine,
HIV infection, CD4 lymphocytes, HIV RNA, and HCV infection.
The VACS Index ranges from 0 to 164 points, with a higher score
indicating greater comorbidity. The VACS Index has been associated
with an increased risk of hospitalization and death in patients with
and without HIV infection (Blackstock et al., 2013; Justice et al., 2013;
Tate et al., 2013). In HIV-negative patients, HIV RNA is considered
undetectable.
Follow-Up, Comorbidity and Outcomes
The patients were followed up until September 30, 2018 through
in-person visits and review of the ED visits and hospitalization
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e-health records of the Catalan health department. The diagnoses
made during the ED visits and hospitalization were coded
according to the 10th revision of the International
Classification of Diseases (ICD-10). The diagnostic coding was
carried out by two members of the research team (AS and RM)
independently; coding discrepancies were resolved by consensus.
Mortality was analyzed by cross-referencing the data with the
National Death Index as of September 30, 2018. The causes of
death were established by reviewing the medical history.
Ethics
All patients gave written informed consent, and the study design
was approved by the Ethics Committee of the Germans Trias i
Pujol University Hospital (approval number PI-13-082). The
methods were in compliance with the ethical standards for
medical research and the principles of good clinical practice in
accordance with the World Medical Association’s Declaration of
Helsinki.
Statistical Analysis
Descriptive statistics were expressed as median and interquartile
range (IQR) for quantitative variables and as absolute frequencies
and percentages for qualitative variables.
We used the chi-square test to detect significant differences in
qualitative variables and t-Student test for differences in quantitative
variables. The Kruskal-Wallis equality-of-populations rank test and
Mann-Whitney U test were used to analyze differences in the
distribution of episodes during follow-up.
Rates were calculated in p-y by dividing the number of observed
events during the study period by the sum of all individual follow-
up times. The survival estimates were analyzed using the Kaplan-
Meier curves. Cox regression models were used to analyze the risk
factors of first hospitalization after discharge andmortality. The sex,
variables related to substance use, and the VACS Index score were
included in the analysis. All covariates that were statistically
significant in the univariate analysis were included in the
multivariate analysis. Prior to implementing the statistical
models, we checked the proportional hazard assumptions using
tests and graphs based on the Schoenfeld residuals.
p-values <0.05 were considered statistically significant.
Statistical analysis was performed using Stata software (version
11.1, College Station, Texas, United States).
RESULTS
Patient Characteristics at Baseline
The study included 175 patients (77.7% men) aged 35 years [IQR:
30–41 years]. The age of onset of cocaine use was 22 years [IQR:
18–26 years], with 59.4% of the patients being intranasal users, 33.5%
injectors, and 7.1% smokers. Moreover, 22.9% of the patients had
concomitant AUD. According to the screening for illegal drugs in
urine samples, 39.4% were cannabis users and 9% opiate users.
Overall, 58.1% of the patients used alcohol or other substances in
addition to cocaine. The most common combinations of substances
were cocaine and cannabis (27.5%), cocaine and alcohol (14.4%), and
cocaine, alcohol, and cannabis (7.5%).
The laboratory test results for hemoglobin, total cholesterol,
and gamma-glutamyl transferase were 14.2 g/dl [IQR:
12.9–15.3 g/dl], 170 mg/dl [IQR: 147–201 mg/dl], and 28 U/L
[IQR: 17–62 U/L], respectively. Moreover, 24.7% of the
patients were HIV-positive and 47.4% were anti-HCV positive.
The body mass index (BMI) was 19.5 kg/m2 [IQR:
16.4–23.0 kg/m2]. The median VACS Index score on
admission was 10 points [IQR: 0–22; range 0–69]. Table 1
shows the sociodemographic characteristics, alcohol and
substance use, and clinical and blood parameters.
Follow-Up, ED Visits, Hospitalizations and
Comorbidity
Table 2 shows the socio-demographics, substance use characteristics,
and clinical and blood parameters of CUD patients that were
hospitalized during follow-up. Hospitalization was significantly
more frequent in women (p  0.049), in those with antecedent of
injecting drug use (p 0.028), and inHIV-positive andHCV-positive
patients (p  0.001 and p  0.047, respectively).
TABLE 1 | Sociodemographic characteristics, alcohol and substance use, and
clinical and blood parameters in 175 patients admitted for the treatment of
CUD in metropolitan Barcelona, Spain.
N = 175
Men, n (%) 136 (77.7)
Age, median [IQR] 35 [30–41]
BMI, (kg/m2) (n  144), median [IQR] 19.5 [16.4–23.0]
Drug related parameters n (%)
Age at starting cocaine use, median [IQR] 22 [18–26]




Duration of CUD (months) (n  164), median [IQR] 111 [36–180]
AUD 40 (22.9)
Urine screening at admission
Opiates (n  158) 14 (8.9)
Cannabis (n  160) 63 (39.4)
Antecedent of injection drug use (n  172) 82 (47.7)
Hematology parameters Median [IQR]
Platelet count (x109L) (n  174) 219 [184–270]
Hemoglobin (g/dL) (n  174) 14.2 [12.9–15.3]
Biochemistry Median [IQR]
Creatinine (mg (dL) (n  173) 0.9 [0.78–0.99]
Glomerular fíltration rate (n  173) 97.6 [83.9–109]
Aspartate aminotransferase (U/L) 24 [18–40]
Alanine aminotransferase (U/L) (n  173) 25 [16–46]
Comorbidity n (%)
HIV Infection (n  174) 43 (24.7)
CD4+ T cell (x109L), median [IQR] 457 [214–730]
Viral load (copies/mL), median [IQR] 1,000 [49–22,000]
HCV Infection (n  173) 82 (47.4)
FIB-4 (n  173), median [IQR] 0.76 [0.54–1.28]
Advanced liver fibrosis (>3.25) 8 (4.6)




AUD, alcohol use disorder; BMI, body mass index; CUD, cocaine use disorder; HCV,
hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range.
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The median follow-up time was 12.1 years [IQR: 8.6–15.1 years]
with a total time of 1,973.2 p-y. At the end of the study, there were
1,292 (80.7%) ED admissions and 308 (19.3%) hospitalizations. The
median number of ED admissions and hospitalizations per patient
were 5 [IQR: 1–10] and 1 [IQR: 0–2], respectively. The vast majority
(85.1%) of the patients presented at least one episode of ED
admission or hospitalization. Statistically significant differences
were observed in the distribution of episodes (either ED
admission or hospitalization) according to gender and HIV
status; specifically, women (z  −2.704, p  0.007) and HIV-
positive patients (z  −2.291, p  0.022) had a greater number
of episodes (Figure 1). The probability of having an ED admission
or hospitalization was 50% after 2.5 years (95% CI: 1.9–3.7 years)
(Figure 2A).
The incidence rate of ED admission or hospitalization was 18.6
× 100 p-y (95% CI: 15.8–21.8 × 100 p-y), which was significantly
higher in women (rate ratio (RR): 1.8, 95% CI: 1.22–2.60,
p  0.002) and in patients with concomitant AUD (RR: 2.0,
95% CI: 1.3–2.9, p < 0.001). Figure 3A shows the incidence of
episodes according to baseline medical comorbidity.
In terms of ED admissions, 19% were related to trauma/
injuries (i.e., fractures, contusions, wounds), 19% to non-
specific/unclassified symptoms, 10% to substance use, and
8.5% to mental disorder.
Regarding hospitalization, almost 40% of the episodes were
related to mental health, 11% to the liver/digestive system, and
10.4% to respiratory conditions (i.e., pneumonia). Figure 4 shows
the distribution of ED admission and hospitalization episodes
according to the main diagnosis.
Table 3 shows the risk factors for hospitalization. Specifically,
being women (hazard ratio (HR): 1.61, 95% CI: 1.02–2.58),
presenting concomitant AUD (HR: 1.42, 95% CI: 1.18–1.71), and
having VACS Index >40 (HR: 2.59, 95% CI: 1.13–5.94) were
significantly associated with a higher probability of hospitalization.
Mortality and Causes of Death
Of the patients included in the study, 15.4% (n  27) died during
the follow-up and the death rate was 1.4 × 100 p-y (95% CI:
0.9–2.0 × 100 p-y). Table 2 shows the differences between those
who died and those who survived; all-cause mortality was
TABLE 2 | Baseline characteristics of CUD patients according to hospitalization and death during follow-up.
Hospitalization Death
Yes No p value Yes No p value
N = 97 N = 78 N = 27 N = 148
Men, n (%) 70 (72.2) 66 (84.6) 0.049 21 (77.8) 115 (77.7) 0.993
Age, median [IQR] 36 [31–41] 34.5 [30–40] 0.392 37 [32–42] 34.5 [30–40.5] 0.323
BMI, (kg/m2) (n  144), median [IQR] 18.5 [15.6–22.0] 21.0 [17.6–23.4] 0.030 19.4 [14.6–22.7] 19.6 [16.7–23.1] 0.334
Drug related parameters
Age at starting cocaine use, median [IQR] 21 [17–26] 19.5 [18–25] 0.484 22 [18–24] 20 [17–26] 0.963
Route of cocaine administration (n  170)
Injected 33 (35.5) 24 (31.2) 0.509 17 (63.0) 40 (28.0) 0.001
Intranasal 52 (55.9) 49 (63.6) 10 (37.0) 91 (63.6)
Smoked 8 (8.6) 4 (5.2) 0 (0) 12 (8.4)
Duration of CUD (months) (n  164), median [IQR] 120 [42–180] 96 [36–180] 0.968 96 [36–204] 114 [48–180] 0.604
AUD 25 (25.8) 15 (19.2) 0.306 4 (14.8) 36 (24.3) 0.279
Urine screening at admission
Opiates (n  158) 8 (9.1) 6 (8.6) 0.909 3 (13.0) 11 (8.1) 0.445
Cannabis (n  160) 34 (37.8) 29 (41.4) 0.639 12 (50.0) 51 (37.5) 0.248
Antecedent of injection drug use (n  172) 52 (55.3) 30 (38.5) 0.028 21 (80.8) 61 (41.8) <0.001
Hematology parameters
Platelet count (×109L) (n  174) 226 [189–279] 210 [181–262] 0.148 193 [139–233] 224 [191–272] 0.005
Hemoglobin (g/dL) (n  174) 14.2 [13–15.2] 14.1 [12.9–15.3] 0.861 14.7 [12.6–15.1] 14.1 [13.0–15.3] 0.973
Biochemistry
Creatinine (mg (dL) (n  173) 0.89 [0.78–0.99] 0.9 [0.78–0.97] 0.876 0.9 [0.74–1.01] 0.89 [0.79–0.99] 0.955
Glomerular fíltrate rate (n  173) 96.5 [82.8–107.5] 98.3 [85.7–112.4] 0.248 97.7 [83.7–112.4] 97.6 [84.1–108.4] 0.997
Aspartate aminotransferase (U/L) 25 [19–39] 23 [17–41] 0.429 38 [22–73] 23 [18–36.5] 0.006
Alanine aminotransferase (U/L) (n  173) 25.5 [16–43.5] 22 [15–51] 0.877 42 [21–65] 23 [15–42] 0.109
Comorbidity
HIV Infection (n  174) 33 (34.4) 10 (12.8) 0.001 14 (51.8) 29 (19.7) <0.001
CD4+ T cell (x109L), median [IQR] 486 [242–771] 382 [202–562] 0.314 364 [202–457] 562 [242–792] 0.097
Viral load (copies/mL), median [IQR] 2,700 [49–22,000] 337 [49–8,100] 0.325 4,050 [49–15,000] 570 [49–22,000] 0.725
HCV Infection (n  173) 52 (54.2) 30 (39.0) 0.047 21 (77.8) 61 (41.8) 0.001
FIB-4, median [IQR] (n  173) 0.76 [0.54–1.30] 0.78 [0.53–1.26] 0.732 1.5 [0.8–2.2] 0.7 [0.5–1.1] <0.001
Advanced liver fibrosis (>3.25) 3 (3.1) 5 (6.5) 0.294 4 (14.8) 4 (2.7) 0.006
VACS index, median [IQR] (n  173) 10 [0–27] 10 [0–15] 0.110 21 [11–33] 10 [0–19] 0.001
<20 64 (66.7) 59 (76.6) 0.349 13 (48.1) 110 (75.3) 0.005
20–39 24 (25.0) 14 (18.2) 9 (33.3) 29 (19.9)
>40 8 (8.3) 4 (5.2) 5 (18.5) 7 (4.8)
AUD, alcohol use disorder; BMI, body mass index; CUD, cocaine use disorder; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range.
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significantly associated with current or past injecting drug use
(p  0.001 and p < 0.001, respectively), HIV infection (p < 0.001),
HCV infection (p < 0.001), advanced liver fibrosis (p  0.006) and
higher scores in VACS Index (p  0.005).
Figure 2B shows the estimate (Kaplan-Meier) of survival after
admission for CUD treatment. Themultivariate analysis showed that
medical comorbidity was the only predictor of death; patients with
VACS >40 showed 3.5 times greater probability of death (HR 3.52,
FIGURE 1 | ED admissions or hospitalizations by (A) sex and (B) HIV infection status in a cohort of 175 patients admitted for treatment of CUD in metropolitan
Barcelona, Spain.
FIGURE 2 | Kaplan-Meier estimates (95% confidence intervals) for (A) ED visits or hospitalization episodes of 175 CUD patients and for (B) survival after being
admitted for detoxification in metropolitan Barcelona, Spain.
FIGURE 3 | Comorbidity (VACS Index)-adjusted incidence rates (95% confidence intervals) of (A) ED admission or hospitalization episodes and (B) mortality in a
cohort of 175 patients seeking treatment of CUD in metropolitan Barcelona, Spain.
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95% CI: 1.19–10.4) compared to patients with VACS Index <20
(Table 3). Figure 3B shows death rates according to VACS Index.
The cause of death was determined in 77.7% (21/27) of cases;
the main causes were drug-related in 40% (n  8; 5 overdoses, 3
unattended deaths in the context of current drug use), cancer in
19% (n  4), infectious diseases in 9.5% (n  2), cardiovascular
diseases in 9.5% (n  2), and liver cirrhosis in 9.5% (n  2).
DISCUSSION
This longitudinal study in patients with CUD who were followed
for 12 years confirms the prognostic value of a comorbidity index
in predicting the risk of hospitalization and death in patients
seeking treatment for the disorder. VACS is a multiorgan system
injury index validated in 2013 for HIV-positive patients, although
it has been described as a reliable index for HIV-negative patients
as well and as a predictor of health outcomes such as
hospitalization (Tate et al., 2013; Barakat et al., 2015; Hotton
et al., 2017). To the best of our knowledge, this is the first time that
VACS Index was analyzed in a cohort of HIV-positive and HIV-
negative patients with CUD. Our results support the use of
medical comorbidity rates in patients with SUD who start
treatment, although more studies are required to confirm these
findings.
In this study, VACS Index at baseline reflectedmoderate organ
system damage, even though 47 and 25% of the patients had HCV
and HIV infection, respectively. Despite moderate comorbidity,
those with a VACS Index score over 40 were up to 2.6 times more
likely to require hospitalization than those with a VACS score
under 20. On the other hand, women with CUD and AUDwere at
a higher risk of hospitalization. Concomitant AUD is frequent in
CUD and has been described as an indicator of poor health
outcomes (Timko et al., 2018). Specifically, cocaethylene, the
metabolite resulting from the concomitant use of alcohol and
cocaine, has a known toxicity (Jones, 2019). This potent stimulant
FIGURE 4 | Distribution of 1,292 ED admissions and 308 hospitalizations according to ICD-10 diagnostic codes.










Women 1.89 (1.21–2.96) 1.61 (1.01–2.58) 1.07 (0.43–2.65)
Age at starting cocaine use: 5 years increase 1.15 (0.93–1.43) 0.93 (0.57–1.52)
Non-intranasal cocaine 0.94 (0.62–1.41) 2.30 (1.05–5.03) 1.64 (0.69–3.92)
Duration of CUD 0.99 (0.99–1.00) 1.00 (0.99–1.01)
AUD 1.23 (1.05–1.44) 1.27 (1.08–1.48) 0.96 (0.67–1.38)
Urine screening at admission
Opiates 0.72 (0.35–1.50) 1.28 (0.38–4.32)
Cannabis 0.84 (0.55–1.29) 1.49 (0.67–3.32)
VACS index
<20 1 1 1 1
20–39 1.30 (0.81–2.08) 1.24 (0.77–2.02) 2.39 (1.02–5.59) 1.86 (0.73–4.72)
>40 2.63 (1.25–5.52) 2.64 (1.20–5.83) 4.35 (1.55–12.2) 3.52 (1.19–10.4)
Statistically significant differences are in bold. AUD, alcohol use disorder; CUD, cocaine use disorder; CI, confidence interval; HR: hazard ratio.
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is more toxic than cocaine itself and has a longer half-life. On the
other hand, the increased risk of hospitalization for women with
CUD requires an accurate evaluation of the continuum of care
and care coordination after discharge.
It was interesting to confirm that medical comorbidity was the
only predictor of death in this cohort with a high prevalence of
polysubstance use. Some studies on CUD indicate that the risk of
death is higher in men, in those with a history of injected drugs, in
those with an early onset of use, in those who drink alcohol, or in
those with psychiatric comorbidity (Arendt et al., 2011; de la
Fuente et al., 2014). However, there are hardly any studies on the
medical comorbidity of CUD other than HIV infection and HCV
infection. VACS Index analyzes kidney and liver function in
addition to age, hemoglobin and HIV and HCV infections, thus
reflecting the general health status. The recent 2019 version
includes albumin, blood cell count, and BMI (Tate et al.,
2019), which may improve the prognostic value of VACS.
It was interesting to note that BMI was below 19.5 kg/m2 in
50% of the patients in this study and below 16.4 kg/m2 in 25%,
which indicates that being underweight might be associated with
CUD or an underlying disease. A population study in adults aged
18–45 years demonstrated that the BMI of cocaine users is lower
than that of non-users, although those BMI values were much
higher than those observed in this study (Qureshi et al., 2014).
On the other hand, death rates in this hospital-based cohort
were higher than that reported by another Spanish study of
patients recruited in outpatient clinics (de la Fuente et al.,
2014), although clearly lower than that reported by our group
in past decades (Sanvisens et al., 2014).
ED admissions for accidents/injuries and non-specific
symptoms were the most frequent during follow-up,
suggesting that they could be related to continued substance
use or complications derived from such use. The first systematic
review and meta-analysis on healthcare utilization in patients
with SUD was published in 2019 and shows that hospitalization
and ED admissions are 5 and 7 times more frequent, respectively,
in this group than in the general population (Lewer et al., 2020).
In Spain, 38.4% of drug-related ED admissions can be attributed
to cocaine (Miró et al., 2019). Furthermore, a study reveals that
18% of those admitted to an ED for cocaine use are readmitted in
the following year (Miro et al., 2010).
Mental health-related complications, accidents/injuries,
respiratory/lung related conditions, and digestive/liver diseases
were other diagnoses frequently observed during follow-up.
About 40% of the episodes were related to SUD either due to
an associated mental illness or to trauma/accidents associated
with substance use. These results are consistent with those
presented in individuals who use illicit drugs (Aitken et al.,
2013; Kendall et al., 2017). The pulmonary complications
resulting from cocaine use could be due to several reasons,
although the route of administration is relevant (Mégarbane
and Chevillard, 2013); cocaine’s respiratory toxicity can be
immediate (i.e., acute lung injury or hypersensitivity reaction)
or delayed (i.e., chronic obstructive pulmonary disease, cancer)
(Mégarbane and Chevillard, 2013). A recent study shows that
cocaine users are at increased risk for pulmonary hypertension
(Alzghoul et al., 2020).
In terms of digestive/liver comorbidity, our findings are
consistent with those observed in other studies (Pavarin et al.,
2011). Liver decompensation was another frequent reason for
clinical attention; however, a study in patients coinfected with
HIV and HCVwas unable to demonstrate an association between
cocaine/crack use and evolution of liver fibrosis (Martel-
Laferrière et al., 2017). Therefore, it is likely that alcohol abuse
in the patients could explain those findings.
Cardiovascular complications in this long-term followed-up
cohort were less frequent than expected, despite the extensive
scientific literature on CUD and acute coronary syndrome (Lippi
et al., 2010; Carrillo et al., 2011). However, the results are
consistent with those reported in other cohorts with low
frequency of coronary ischemic complications (Qureshi et al.,
2014).
This study has several limitations that should be mentioned.
First, socioeconomic and baseline psychiatric comorbidity
data were not available, which could have facilitated the
interpretation of some findings during follow-up. Second,
temporary changes in cocaine use (i.e., remission or
exacerbation of use) were not analyzed. In this sense,
retention in care is critical for achieving remission of CUD.
The high rate of ED admissions of the patients in this study and
the diagnoses of episodes related to continued substance use
suggest low treatment retention. Third, patients from this
study were evaluated with different DSM versions; however,
criteria for admission were similar throughout the study
period and mainly related to the severity of CUD. Fourth,
this study had a limited number of patients, which impairs the
interpretation of some associations due to lack of statistical
power (i.e., route of cocaine administration). In addition, this
study was carried out in a single unit which limits the
generalization of the findings.
In contrast, the strength of this study among patients seeking
treatment for CUD highlights the challenges in measuring
medical comorbidity with an index that has proven to be
useful in the context of SUD. Most studies on cocaine-related
morbidity are conducted in EDs with patients with acute
intoxication (Arendt et al., 2011; Qureshi et al., 2014; Miró
et al., 2019; Santurtún et al., 2020), which prevents an accurate
clinical assessment of comorbidity. Finally, understanding the
risk factors for mortality allows us to target preventive
interventions to increase retention in care among those
seeking treatment for the disorder.
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